Your browser doesn't support javascript.
loading
Cross-sectional increase of adherence to multidisciplinary tumor board decisions.
Hollunder, S; Herrlinger, U; Zipfel, M; Schmolders, J; Janzen, V; Thiesler, T; Güresir, E; Schröck, A; Far, F; Pietsch, T; Pantelis, D; Thomas, D; Vornholt, S; Ernstmann, N; Manser, T; Neumann, M; Funke, B; Schmidt-Wolf, I G H.
Afiliación
  • Hollunder S; Department of Integrated Oncology - CIO Bonn, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany.
  • Herrlinger U; Department of Neurooncology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
  • Zipfel M; Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany.
  • Schmolders J; Department of Orthopedics and Trauma Surgery, University Hospital Bonn, Bonn, Germany.
  • Janzen V; Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany.
  • Thiesler T; Department of Pathology, University Hospital Bonn, Bonn, Germany.
  • Güresir E; Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
  • Schröck A; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany.
  • Far F; Department of Oral, Maxillofacial and Plastic Surgery, University Hospital Bonn, Bonn, Germany.
  • Pietsch T; Department of Neuropathology, University Hospital Bonn, Bonn, Germany.
  • Pantelis D; Department of General, Visceral-, Thoracic and Vascular Surgery, University Hospital Bonn, Bonn, Germany.
  • Thomas D; Department of Radiology, University Hospital Bonn, Bonn, Germany.
  • Vornholt S; Department of Radiology, University Hospital Bonn, Bonn, Germany.
  • Ernstmann N; Department of Psychosomatic Medicine and Psychotherapy, University Hospital Bonn, Bonn, Germany.
  • Manser T; University of Applied Sciences and Arts Northwestern Switzerland, FHNW School of Applied Psychology, Bern, Switzerland.
  • Neumann M; Department of Integrated Oncology - CIO Bonn, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany.
  • Funke B; Department of Integrated Oncology - CIO Bonn, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany.
  • Schmidt-Wolf IGH; Department of Integrated Oncology - CIO Bonn, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany. ingo.schmidt-wolf@ukbonn.de.
BMC Cancer ; 18(1): 936, 2018 Sep 29.
Article en En | MEDLINE | ID: mdl-30268109
ABSTRACT

BACKGROUND:

Cancer research has made great progress in the recent years. With the increasing number of options in diagnosis and therapy the implementation of tumorboards (TUBs) has become standard procedure in the treatment of cancer patients. Adherence tests on tumor board decisions are intended to enable quality assurance and enhancement for work in tumor boards in order to continuously optimize treatment options for cancer patients.

METHODS:

Subject of this study was the adherence of the recommendations made in three of 14 tumorboards, which take place weekly in the Center for Integrated Oncology (CIO) at the University Hospital Bonn. In total, therapy recommendations of 3815 patient cases were checked on their implementation. A classification into four groups has been made according to the degree of implementation. A second classification followed regarding the reasons for differences between the recommendation and the therapy which the patient actually received.

RESULTS:

The study showed that 80.1% of all recommendations in the three TUBs were implemented. 8.3% of all recommendations showed a deviance. Most important reasons for the deviances were patient wish (36.5%), patient death (26%) and doctoral decision, due to the patient's comorbidities or side effects of the treatment (24.1%).Interestingly, deviance in all three tumor boards in total significantly decreased over time.

CONCLUSIONS:

Aim of the study was to clarify the use of tumor boards and find approaches to make them more efficient. Based on the results efficiency might be optimized by increased consideration of patients` preferences, improved presentation of patient-related data, more detailed documentation and further structuring of the tumor board meetings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adhesión a Directriz / Investigación Interdisciplinaria / Oncología Integrativa / Neoplasias Tipo de estudio: Guideline / Prevalence_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adhesión a Directriz / Investigación Interdisciplinaria / Oncología Integrativa / Neoplasias Tipo de estudio: Guideline / Prevalence_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Alemania